NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, News & Analysis

$1.41
+0.04 (+2.92 %)
(As of 08/19/2019 04:00 PM ET)
Today's Range
$1.3601
Now: $1.41
$1.43
50-Day Range
$1.20
MA: $3.91
$6.50
52-Week Range
$1.13
Now: $1.41
$11.88
Volume702,236 shs
Average Volume969,666 shs
Market Capitalization$149.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.21 million
Book Value($0.61) per share

Profitability

Net Income$-120,550,000.00
Net Margins-208.07%

Miscellaneous

Employees202
Market Cap$149.84 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.


Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.13. The biopharmaceutical company had revenue of $9.68 million for the quarter, compared to analyst estimates of $28.52 million. Lexicon Pharmaceuticals's revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.33) EPS. View Lexicon Pharmaceuticals' Earnings History.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Lexicon Pharmaceuticals.

What price target have analysts set for LXRX?

6 brokers have issued 12 month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they expect Lexicon Pharmaceuticals' share price to reach $8.00 in the next year. This suggests a possible upside of 467.4% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/3/2019)
  • 2. Needham & Company LLC analysts commented, "Lexicon reported 1Q19 U.S. Xermelo sales of $6.7M, below our $8.0M est. Mgmt reiterated 2019 guidance for 20+% y/y U.S. sales growth. Sanofi and Lexicon announced Zynquista approval for by EMA 4/26/19. Lexicon is entitled to a milestone payment in 2Q19 tied to the approval, which we estimate to be around $30M. Discussions w/ FDA around CRL in T1D are planned. No guidance on timing. We previously removed the revenue stream from our model. The first of several Phase 3 T2D trials are expected to generate results beginning in 2Q19 (metformin combination first). We believe the stock is likely to become more attractive if Zynquista is sufficiently differentiated from SGLT2 drugs in T2D, particularly around renal impairment. Maintain HOLD." (5/2/2019)

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

News coverage about LXRX stock has been trending negative on Monday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Lexicon Pharmaceuticals.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a drop in short interest in July. As of July 31st, there was short interest totalling 7,668,900 shares, a drop of 17.4% from the June 30th total of 9,285,500 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is currently 7.1 days. Approximately 7.5% of the shares of the stock are sold short. View Lexicon Pharmaceuticals' Current Options Chain.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.99%), BlackRock Inc. (3.82%), First Manhattan Co. (2.78%), Pictet Asset Management Ltd. (0.63%), Pictet Asset Management Ltd. (0.63%) and Northern Trust Corp (0.52%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Which major investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Bank of America Corp DE, BlackRock Inc., Jacobs Levy Equity Management Inc., Pinnacle Associates Ltd., Northern Trust Corp and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Which major investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., First Manhattan Co., Virtus ETF Advisers LLC, Morgan Stanley, Pictet Asset Management Ltd., Pictet Asset Management Ltd., AXA and GSA Capital Partners LLP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $1.41.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $149.84 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.


MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  369 (Vote Underperform)
Total Votes:  755
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel